Longer life expectancy leads to a significant increase in people older than 80 years of age. That’s the benefit of modern health care.
Unfortunately, an increase in life expectancy and the aging population leads to dramatical increases in age-related health issues. Heart disease and cancer are the leading age-related illnesses. The health sciences have made a significant progress in developing new preventive or curative treatment options for these diseases.
Dementia, the collective name for cognitive decline and self-awareness in older individuals, is one of the most devastating age-related conditions. The major cause of dementia is the Alzheimer’s Disease, a new case diagnosed every 66 seconds. The socio-economic expense of Alzheimer’s Disease is expected to exceed $ 1 trillion in 2018.
Despite tremendous efforts by scientist, physicians and biopharma companies, a curative and disease-modifying treatment for Alzheimer’s Disease remains elusive. Many promising therapeutic candidates failed or were not suitable for human.
A promising new drug called BAN2401 is currently in clinical trials, specifically in Phase 2. Data reveals that this drug was able to slow down the progress of Alzheimer’s Disease in a small population of patients. However, only Phase 3 studies conducted with a much larger patient population and more rigorous criteria for efficacy can decide between new hope or another disappointment.